Homoeopathic Pathogenetic Trial of drug code 144: a multicenter, double blind, randomized, placebo controlled trial
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 45
- 试验地点
- 7
- 主要终点
- The pathogenesis of drug code 144
研究概览
简要总结
The study is a double blind randomized placebo control clinical trial to see the pathogenetic effect of the investigational drug substance on healthy volunteers. The drug has to be proved in ascending potencies. The drug is administered after PME and 1-2 weeks run-in-period. The provers are advised to take 4 doses in a day (4 hourly) for 3 days from the prescribed batch (potency) of the coded drug. After the completion of the batch(potency), one month washout period will be maintained in all provers, before the next batch (potency) is initiated. After finishing all the batches (potencies), the provers will undergo Post Trial Medical Examination. The codes will be broken after the completion of the study and data will be compiled to know the pathogenesis of this drug substance and analysed to find characteristic symptom (prescribing indication). The proving symptoms will be identified and segregated from the symptoms produced in placebo group. The proving symptoms will from the drug pathogenesis.
研究设计
- 研究类型
- Interventional
- 分配方式
- Computer generated randomization
- 盲法
- Participant and Investigator Blinded
入排标准
- 年龄范围
- 18.00 Year(s) 至 60.00 Year(s)（—）
- 性别
- All
入选标准
- •1.Healthy individuals with no apparent disease and normal routine laboratory parameters during screening 2.Healthy individuals identified as fit for proving by experts 3.Intelligent enough to record carefully the facts, subjective and objective symptoms generated by the IPS during proving.
- •4.Able to be informed of the nature of the study and willing to give written informed consent.
排除标准
- •1.Any disease or condition which might compromise the hematopoietic, renal, endocrine, pulmonary, central nervous system, cardiovascular, immunological, dermatological, gastro-intestinal or any other body system 2.Persons with colour blindness.
- •3.Persons who have undergone surgery in last two months.
- •4.Planned medical / dental treatment during the proving period including herbal or dietary supplements, procedures, or medications that are likely to interfere with, or substantially alter, responsiveness to the proving substance.
- •5.Volunteers on regular medication (allopathic, ayurvedic, homoeopathic, naturopathic, unani, etc.) for any acute or chronic disease.
- •6.Participant must not be on any homoeopathic remedy in the preceding one month and have had no significant change in health status in last one month.
- •7.Emotionally disturbed, hysterical or anxious persons.
- •8.Persons having known history of allergies, food hypersensitivity, etc.
- •9.Women during pregnancy, puerperium and while breast-feeding and women who have undergone hysterectomy.
- •10.Smokers who smoke more than 10 cigarettes per day 11.Recent history of alcoholism / drug addictions or unlikely to refrain from excessive alcohol consumption / drug intake during the study period 12.Participation in another clinical or proving trial during the last 6 months.
结局指标
主要结局
The pathogenesis of drug code 144
时间窗: At Baseline and after 1 year (completion of the trial)
次要结局
未报告次要终点